Propylthiouracil – Uses, Dosage, Side Effects, Interactions Propylthiouracil is a Thyroid Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group. It has a role as an antithyroid drug, a carcinogenic agent, an antimetabolite, a hormone antagonist, an EC 1.14.13.39 (nitric oxide synthase) inhibitor, an antioxidant, and an antidote to paracetamol poisoning. It is functionally related to a uracil. A thiourea antithyroid agent. Propylthiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of thyroxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeia, 30th ed, p534) A thiourea antithyroid agent. Propylthiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of thyroxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. Mechanism of Action Propylthiouracil binds to thyroid peroxidase and thereby inhibits the conversion of iodide to iodine. Thyroid peroxidase normally converts iodide to iodine (via hydrogen peroxide as a cofactor) and also catalyzes the incorporation of the resulting iodide molecule onto both the 3 and/or 5 positions of the phenol rings of tyrosines found in thyroglobulin. Thyroglobulin is degraded to produce thyroxine (T4) and tri-iodothyronine (T3), which are the main hormones produced by the thyroid gland. Therefore propylthiouracil effectively inhibits the production of new thyroid hormones or Propylthiouracil inhibits the synthesis of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin; the drug also inhibits the coupling of these iodotyrosyl residues to form iodothyronine. Although the exact mechanism(s) have not been fully elucidated, propylthiouracil may interfere with the oxidation of iodide ion and iodotyrosyl groups. Based on limited evidence it appears that the coupling reaction is more sensitive to antithyroid agents than the iodination reaction. Propylthiouracil does not inhibit the action of thyroid hormones already formed and present in the thyroid gland or circulation nor does the drug interfere with the effectiveness of exogenously administered thyroid hormones. Patients whose thyroid gland contains a relatively high concentration of iodine (e.g., from prior ingestion or from administration during diagnostic radiologic procedures) may respond relatively slowly to antithyroid agents. Unlike methimazole, propylthiouracil inhibits the peripheral deiodination of thyroxine to triiodothyronine. Although the importance of this inhibition has not been established, propylthiouracil has a theoretical advantage compared with methimazole or carbimazole in patients with thyrotoxic crisis, since a decreased rate of conversion of circulating thyroxine to triiodothyronine may be clinically beneficial in these patients. Propylthiouracil is a thiourea antithyroid agent. Grave’s disease is the most common cause of hyperthyroidism. It is an autoimmune disease where an individual’s own antibodies attach to thyroid-stimulating hormone receptors within cells of the thyroid gland and then trigger the overproduction of thyroid hormone. The two thyroid hormones manufactured by the thyroid gland, thyroxine (T4) and triiodothyronine (T3), are formed by combining iodine and a protein called thyroglobulin with the assistance of an enzyme called peroxidase. PTU inhibits iodine and peroxidase from their normal interactions with thyroglobulin to form T4 and T3. This action decreases thyroid hormone production. PTU also interferes with the conversion of T4 to T3, and, since T3 is more potent than T4, this also reduces the activity of thyroid hormones. The actions and use of propylthiouracil are similar to those of methimazole. Indications Antimetabolites, Antithyroid Agents Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave’s disease). Propylthiouracil is an antithyroid medication used in the therapy of hyperthyroidism and Graves disease. Propylthiouracil has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that can be severe and even fatal. Propylthiouracil /is/ indicated in the treatment of hyperthyroidism, including prior to surgery or radiotherapy, and as adjuncts in the treatment of thyrotoxicosis or thyroid storm. Propylthiouracil may be preferred over methimazole for use in thyroid storms since propylthiouracil inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3). Paradoxically propylthiouracil has been shown to reverse histological changes of alcoholic hepatitis in rats and has been proposed as a possible treatment for this condition in men. Twelve-day pretreatment with PTU prevented the Tylenol-induced increase in transaminase activities. An increase in hepatic reduced glutathione levels and prevention of inflammatory response to necrotic liver tissue appeared to be mechanisms in the protective action of hypothyroidism. Hyperthyroidism treatment Used if methimazole or radioactive iodine treatment is contraindicated or as an alternative treatment option in a patient with Graves disease or toxic multinodular goiter[rx] Used before thyroidectomy or radioactive iodine therapy to treat hyperthyroidism In thyroid storm and thyrotoxicosis crisis (off-label treatment), to treat the hyperthyroidism. It is a preferred antithyroid drug in the first trimester of pregnancy. For patients with Graves’ disease and hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. Contraindications Contraindications include a previous history of hypersensitivity to PTU or any of its drug components. Caution is advised in patients with hepatic impairment or myelosuppression and pediatric patients. Dosages Strengths: 50 mg Hyperthyroidism Initial dose: 100 mg orally every 8 hours Maintenance dose: 100 to 150 mg orally daily administered in 3 equally divided doses approximately every 8 hours For patients with severe hyperthyroidism, very large goiters, or both, the initial dose may be increased to 400 mg, or for the occasional patient, up to 600 to 900 mg daily initially (administered in 3 equally divided doses as approximately 8-hour intervals). Thyroid Storm Initial dose: 100 mg orally every 8 hours Maintenance dose: 100 to 150 mg orally daily administered in 3 equally divided doses approximately every 8 hours For patients with severe hyperthyroidism, very large goiters, or both, the initial dose may be increased to 400 mg, or for the occasional patient, up to 600 to 900 mg daily initially (administered in 3 equally divided doses as approximately 8-hour intervals). Pediatric Dose for Hyperthyroidism 6 years or older: Initial dose: 50 mg orally daily in 3 equally divided doses approximately every 8 hours Carefully titrate based on clinical response and evaluation of TSH and free T4 levels OR, 6 to 10 years of age: Initial dose: 50 to 150 mg orally daily in 3 equally divided doses approximately every 8 hours 10 years or older: Initial dose: 150 to 300 mg orally daily in 3 equally divided doses approximately every 8 hours Maintenance dose: 50 mg orally twice a day when euthyroid Although cases of severe liver injury have been reported with doses as low as 50 mg per day, most cases were associated with doses of 300 mg per day and higher. or The available propylthiouracil tablet has 50 mg of the drug, and storage should be at room temperature. The dosage is as follows: Adults: Propylthiouracil is administered orally, initially as 300 mg/day in three divided doses every 8 hours (may reach up to 600 to 900 mg/day). After the initial treatment, the general maintenance dose is 100 to 150 mg/day. The dose is adjusted to maintain normal TSH, T3, and T4 levels. Graves disease (off-label): PTU can be started as an initial dose of 50 to 150 mg three times a day Thyrotoxic crisis/thyroid storm (off-label): The American Thyroid Association recommends 500 to 1000 mg as a loading dose of PTU, which can be followed by 250 mg every 4 hours. Recommendations are widely variable, and comparative trials have not taken place.[rx] Pediatric: Due to severe liver toxicity reported with the use of PTU, it is no longer approved by the United States Food and Drug Administration (FDA) in pediatric patients. Geriatric: Clinical studies incorporating the effects of PTU in patients over 65 years are lacking. PTU should be used cautiously in the geriatric age group, owing to an increased likelihood of co-morbidities and declined organ function in the elderly. Dose Adjustments Elderly: Dose selection should be cautious, reflecting the greater frequency of decreased hepatic, renal, cardiac function, and concomitant disease or other drug therapy. Precautions US BOXED WARNINGS: Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with this drug. These reports of hepatic reactions include cases requiring liver transplantation in adult and pediatric patients. This drug should be reserved for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism. This drug may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy. Safety and efficacy have not been established in patients younger than 6 years. Administration advice: Take orally in equally divided doses at approximately 8-hour intervals Missed dose: If a dose is missed, take it as soon as you remember; if it is almost time for your next dose, skip the missed dose. Do not double your dose. General: Patients treated with this drug should be under close surveillance due to the potential for serious adverse effects. In general, this drug should only be considered in patients who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. It may be the treatment of choice for the first trimester of pregnancy due to methimazole use being associated with fetal abnormalities; after the first trimester it may be preferable to switch to methimazole. Monitoring: Routine monitoring of TSH and free T4 levels is necessary to avoid under or over treatment Consider monitoring prothrombin time if there are concerns of bleeding; prothrombin time should be monitored before surgical procedures Monitor blood counts if there are signs and symptoms of agranulocytosis Routine liver function testing may not attenuate the risk of severe liver injury; however, immediately perform liver function testing if there are any symptoms of hepatic dysfunction Patient advice: Patient should be instructed to read the US FDA-approved patient labeling (Medication Guide) Patients should understand the importance of contacting their healthcare provider promptly if they experience any signs or symptoms of liver dysfunction, low blood counts, bleeding, or vasculitis. Women should be instructed to speak to their healthcare provider if they are pregnant or plan to become pregnant. This drug may cause dizziness, drowsiness, or sleepiness; do not drive or perform hazardous tasks until you know how this drug affects you. Side Effects The Most Common difficulty tasting food numbness, burning, or tingling of the hands or feet joint or muscle pain dizziness swelling of the neck Black, tarry stools chest pain chills cough fever painful or difficult urination shortness of breath sore throat sores, ulcers, or white spots on the lips or in the mouth swollen glands unusual bleeding or bruising unusual tiredness or weakness Dark-colored urine a general feeling of discomfort, illness, or weakness headache light-colored stools nausea or vomiting stomach pain, continuing upper right abdominal or stomach pain yellow eyes and skin More Common Dermatologic: erythema nodosum, exfoliative dermatitis, urticaria, skin ulcers, skin rash, alopecia, Stevens-Johnson syndrome, toxic epidermal necrolysis Renal: acute kidney injury, acute interstitial nephritis Gastrointestinal: loss of taste, taste perversion, nausea, vomiting, stomach pain, sial adenopathy Neurological: neuritis, headache, paresthesia, drowsiness, vertigo Hematological: lymphadenopathy, splenomegaly, leukopenia, aplastic anemia, lymphadenopathy, hemorrhage, hypoprothrombinemia Respiratory: pulmonary alveolar hemorrhage, interstitial pneumonitis Drug fever Lupus-like syndrome[rx][rx] Carcinogenesis: pituitary adenomas, thyroid hyperplasia, and carcinoma after more than one year of continuous PTU usage. Infertility sore throat, fever, chills, cough, or other signs of infection headache skin rash, hives, blisters, bumps or peeling dark, rust-colored, brown or foamy urine swelling of the face, eyes, stomach, arms, hands, feet, ankles, or lower legs chest pain shortness of breath or wheezing coughing up blood Rare Abdominal or stomach pain agitation bleeding gums bleeding under the skin blood in the urine or stools bloody or cloudy urine burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings coma confusion cough or hoarseness cracks in the skin decreased urine output depression difficulty with breathing difficulty with moving dizziness drowsiness feeling of fullness fever with or without chills general feeling of discomfort, illness, or weakness high blood pressure hostility irritability joint pain lethargy loss of appetite and weight loss of heat from the body lower back or side pain muscle aching or cramping muscle pain or stiffness muscle twitching numbness or tingling of the hands, feet, or face pain in the ankles or knees painful, red lumps under the skin, mostly on the legs pinpoint red spots on the skin rapid weight gain red, swollen skin redness, soreness, or itching skin scaly skin seizures soreness of the muscles sores on the skin sores, ulcers, or white spots on the lips or in the mouth sores, welting, or blisters stupor swelling of the face, ankles, hands, feet, or lower legs swollen joints swollen salivary glands swollen, painful, or tender lymph glands in the neck, armpit, or groin tightness in the chest unusual weight gain wheezing Drug Interactions DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Abatacept. Abciximab Propylthiouracil may increase the anticoagulant activities of Abciximab. Acalabrutinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Acalabrutinib. Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Propylthiouracil. Acenocoumarol Propylthiouracil may increase the anticoagulant activities of Acenocoumarol. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Propylthiouracil. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Propylthiouracil. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Propylthiouracil. Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Acipimox. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Propylthiouracil. Adenovirus typ The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Propylthiouracil. Afatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Afatinib. Aldesleukin The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Aldesleukin. Alectinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Alectinib. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Propylthiouracil. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Propylthiouracil. Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Alendronic acid. Allogeneic pr The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Propylthiouracil. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Propylthiouracil. Alteplase Propylthiouracil may increase the anticoagulant activities of Alteplase. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Propylthiouracil. Aminophylline Propylthiouracil may decrease the excretion rate of Aminophylline which could result in a higher serum level. Aminosalicylic acid The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Aminosalicylic acid. Amiodarone The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Amiodarone. Amitriptyline The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Amitriptyline. Amitriptylinoxide The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Amitriptylinoxide. Amoxapine The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Amoxapine. Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Propylthiouracil. Amphotericin B The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Amphotericin B. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Propylthiouracil. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Propylthiouracil. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Propylthiouracil. Ancrod Propylthiouracil may increase the anticoagulant activities of Ancrod. Anifrolumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Anifrolumab. Anistreplase Propylthiouracil may increase the anticoagulant activities of Anistreplase. Anthrax i The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Propylthiouracil. Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Propylthiouracil. Antilymphocyte i The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa Propylthiouracil may increase the anticoagulant activities of Antithrombin Alfa. Antithrombin III Propylthiouracil may increase the anticoagulant activities of Antithrombin III human. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Propylthiouracil. Apixaban Propylthiouracil may increase the anticoagulant activities of Apixaban. Apremilast The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Apremilast. Ardeparin Propylthiouracil may increase the anticoagulant activities of Ardeparin. Argatroban Propylthiouracil may increase the anticoagulant activities of Argatroban. Arsenic trioxide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Arsenic trioxide. AstraZeneca The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Propylthiouracil. Atorvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Atorvastatin. Avacopan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Avacopan. Avapritinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Avapritinib. Axitinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Axitinib. Azacitidine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Azathioprine. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Propylthiouracil. Bacillus calmette The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Propylthiouracil. Bacillus calm The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Propylthiouracil. Baclofen The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Propylthiouracil. Baricitinib The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Propylthiouracil. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Propylthiouracil. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Propylthiouracil. Belatacept The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belumosudil. Bemiparin Propylthiouracil may increase the anticoagulant activities of Bemiparin. Bendamustine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Propylthiouracil. Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Propylthiouracil. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Propylthiouracil. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Propylthiouracil. Betrixaban Propylthiouracil may increase the anticoagulant activities of Betrixaban. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Propylthiouracil. Bezafibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Bezafibrate. Bimekizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Bimekizumab. Bivalirudin Propylthiouracil may increase the anticoagulant activities of Bivalirudin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Propylthiouracil. Blinatumomab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Blinatumomab. Bordetella pertus The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Propylthiouracil. Bosutinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brentuximab vedotin. Brigatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Brigatinib. Brodalumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brodalumab. Bromotheophylline Propylthiouracil may decrease the excretion rate of Bromotheophylline which could result in a higher serum level. Budesonide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Budesonide. Bumetanide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Bumetanide. Busulfan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Busulfan. Butriptyline The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Butriptyline. Cabazitaxel The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cabazitaxel. Cabozantinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Cabozantinib. Caffeine Propylthiouracil may decrease the excretion rate of Caffeine which could result in a higher serum level. Canakinumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Canakinumab. Cangrelor Propylthiouracil may increase the anticoagulant activities of Cangrelor. Capecitabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Propylthiouracil. Capmatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Capmatinib. Captopril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Captopril. Carbamazepine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carbamazepine. Carbimazole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Propylthiouracil. Carboplatin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Propylthiouracil. Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Propylthiouracil. Ceritinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ceritinib. Cerivastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Propylthiouracil. Certolizumab pegol The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Propylthiouracil. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Propylthiouracil. Chloroquine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Chloroquine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Propylthiouracil. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Propylthiouracil. Ciclesonide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ciclesonide. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Propylthiouracil. Cimetidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Propylthiouracil. Ciprofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ciprofibrate. Ciprofloxacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Propylthiouracil. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Propylthiouracil. Citalopram The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Propylthiouracil. Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Propylthiouracil. Clobetasol propio The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clofarabine. Clofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Clofibrate. Clomipramine The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Clomipramine. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Propylthiouracil. Clostridiu The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Clozapine The risk or severity of neutropenia can be increased when Propylthiouracil is combined with Clozapine. Colchicine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Colchicine. Corticotropin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Crizotinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Crizotinib. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Propylthiouracil. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Propylthiouracil. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Propylthiouracil. Cyclosporine Propylthiouracil may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Propylthiouracil. Cytarabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cytarabine. Dabigatran Propylthiouracil may increase the anticoagulant activities of Dabigatran. Dabigatran etexilate Propylthiouracil may increase the anticoagulant activities of Dabigatran etexilate. Dacarbazine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dacarbazine. Dacomitinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dactinomycin. Dalteparin Propylthiouracil may increase the anticoagulant activities of Dalteparin. Danaparoid Propylthiouracil may increase the anticoagulant activities of Danaparoid. Daptomycin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propylthiouracil. Dasatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Decitabine. Defibrotide Propylthiouracil may increase the anticoagulant activities of Defibrotide. Deflazacort The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Propylthiouracil. Desipramine The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Desipramine. Desirudin Propylthiouracil may increase the anticoagulant activities of Desirudin. Deslanoside The serum concentration of Deslanoside can be increased when it is combined with Propylthiouracil. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Propylthiouracil. Desvenlafaxine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Desvenlafaxine. Deucravacitinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dexamethasone. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Propylthiouracil. Dextran Propylthiouracil may increase the anticoagulant activities of Dextran. Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Propylthiouracil. Diazepam The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Diazepam. Dibenzepin The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Dibenzepin. Dicoumarol Propylthiouracil may increase the anticoagulant activities of Dicoumarol. Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Propylthiouracil. Difluocortolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Difluocortolone. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Propylthiouracil. Digoxin The serum concentration of Digoxin can be increased when it is combined with Propylthiouracil. Dimethyl fumarate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dinutuximab. Dipyridamole Propylthiouracil may increase the anticoagulant activities of Dipyridamole. Diroximel fumarate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Diroximel fumarate. Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Propylthiouracil. Docetaxel The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Docetaxel. Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Propylthiouracil. Dosulepin The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Dosulepin. Doxepin The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Doxepin. Doxorubicin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Doxorubicin. Drotrecogin alfa Propylthiouracil may increase the anticoagulant activities of Drotrecogin alfa. Duloxetine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Duloxetine. Dyphylline Propylthiouracil may decrease the excretion rate of Dyphylline which could result in a higher serum level. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Propylthiouracil. Eculizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Eculizumab. Edetic acid Propylthiouracil may increase the anticoagulant activities of Edetic acid. Edoxaban Propylthiouracil may increase the anticoagulant activities of Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Propylthiouracil. Efgartigimod alfa The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Efgartigimod alfa. Emapalumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Emapalumab. Enalapril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Enalapril. Enoxaparin Propylthiouracil may increase the anticoagulant activities of Enoxaparin. Entrectinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Entrectinib. Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Propylthiouracil. Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Propylthiouracil. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Propylthiouracil. Epoprostenol Propylthiouracil may increase the anticoagulant activities of Epoprostenol. Eprosartan The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Eprosartan. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Propylthiouracil. Erdafitinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Erdafitinib. Eribulin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Eribulin. Erlotinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Erlotinib. Escitalopram The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Escitalopram. Estetrol The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Estetrol. Estramustine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Estramustine. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Propylthiouracil. Ethanol The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ethanol. Ethionamide The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ethionamide. Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Propylthiouracil. Etoposide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Etoposide. Etrasimod The risk or severity of immunosuppression can be increased when Propylthiouracil is combined with Etrasimod. Everolimus The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Everolimus. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Propylthiouracil. Fedratinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fedratinib. Fenofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fenofibrate. Fenofibric acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fenofibric acid. Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Propylthiouracil. Filgotinib The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Filgotinib. Fingolimod Propylthiouracil may increase the immunosuppressive activities of Fingolimod. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Propylthiouracil. Flucytosine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fludrocortisone. Fluindione Propylthiouracil may increase the anticoagulant activities of Fluindione. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Propylthiouracil. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocinolone acetonide. Fluocinonide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Propylthiouracil. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Propylthiouracil. Fluoxetine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Propylthiouracil. Fluprednisolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluprednisolone. Fluticasone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluticasone propionate. Fluvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fluvastatin. Fluvoxamine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fluvoxamine. Fondaparinux Propylthiouracil may increase the anticoagulant activities of Fondaparinux. Fostamatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fostamatinib. Fusidic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Fusidic acid. Ganciclovir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ganciclovir. Gefitinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Gefitinib. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Propylthiouracil. Gemfibrozil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Gemfibrozil. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil. Gilteritinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Gilteritinib. Glatiramer The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Glatiramer. Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Propylthiouracil. Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Propylthiouracil. Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Propylthiouracil. Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Propylthiouracil. Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Propylthiouracil. Golimumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Golimumab. GSK-3844766A The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Propylthiouracil. Guselkumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Propylthiouracil. Heparin Propylthiouracil may increase the anticoagulant activities of Heparin. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Propylthiouracil. Hepatitis B Vacc The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Propylthiouracil. Human adenovirus e The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Propylthiouracil. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Propylthiouracil. Hydrocortisone acetate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydrocortisone acetate. Hydrocortisone butyrate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydrocortisone butyrate. Hydrocortisone succinate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Propylthiouracil. Hydroxychloroquine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydroxychloroquine. Hydroxyurea The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydroxyurea. Ibandronate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ibandronate. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil. Ibrutinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ibrutinib. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Propylthiouracil. Idarubicin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idarubicin. Idelalisib The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ifosfamide. Iloprost The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Iloprost. Imatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Imatinib. Imipramine The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Imipramine. Indinavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Propylthiouracil. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Propylthiouracil. Inebilizumab The risk or severity of infection can be increased when Propylthiouracil is combined with Inebilizumab. Infigratinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Infigratinib. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Propylthiouracil. Influenza The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Propylthiouracil. Influenza A vir The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Propylthiouracil. Influenza A The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Propylthiouracil. Influenza A virus The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Propylthiouracil. Influenza A virus A The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Propylthiouracil. Influenza A viru The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Propylthiouracil. Influenza The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Propylthiouracil. Influenza A The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Influenza A virus The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Influenza B virus The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Influenza B virus The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Propylthiouracil. Influenza B virus The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Influenza B virus B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Propylthiouracil. Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Propylthiouracil. Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Propylthiouracil. Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Propylthiouracil. Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Propylthiouracil. nsulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Propylthiouracil. Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Propylthiouracil. Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Propylthiouracil. Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Propylthiouracil. Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Propylthiouracil. Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Propylthiouracil. Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Propylthiouracil. Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Propylthiouracil. Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Propylthiouracil. Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Propylthiouracil. Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Propylthiouracil. Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Propylthiouracil. Iodide I-131 The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Propylthiouracil. Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Propylthiouracil. Ipecac The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ipecac. Irinotecan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Irinotecan. Isoniazid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Isoniazid. Isoprenaline The risk or severity of adverse effects can be increased when Isoprenaline is combined with Propylthiouracil. Isotretinoin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Isotretinoin. Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Propylthiouracil. Ivermectin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ivermectin. Ixabepilone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ixekizumab. Janssen COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Propylthiouracil. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil. Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Propylthiouracil. Lamivudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Lamivudine. Lapatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Lapatinib. Larotrectinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Larotrectinib. Leflunomide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Propylthiouracil. Lenvatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Lenvatinib. Lepirudin Propylthiouracil may increase the anticoagulant activities of Lepirudin. Lercanidipine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Propylthiouracil. Letrozole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Letrozole. Leuprolide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propylthiouracil. Levonordefrin The risk or severity of adverse effects can be increased when Levonordefrin is combined with Propylthiouracil. Linezolid The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Linezolid. Lipegfilgrastim Propylthiouracil may increase the myelosuppressive activities of Lipegfilgrastim. Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Propylthiouracil. Lomifylline Propylthiouracil may decrease the excretion rate of Lomifylline which could result in a higher serum level. Lomustine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Lomustine. Lopinavir The serum concentration of Propylthiouracil can be increased when it is combined with Lopinavir. Lovastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Propylthiouracil. Macimorelin The therapeutic efficacy of Macimorelin can be decreased when used in combination with Propylthiouracil. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Propylthiouracil. Measles virus vacci The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Propylthiouracil. Mebeverine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Mebeverine. Mechlorethamine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mechlorethamine. Mefloquine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Propylthiouracil. Melphalan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Propylthiouracil. Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Propylthiouracil. Mepolizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Meprednisone. Mercaptopurine Propylthiouracil may decrease the excretion rate of Mercaptopurine which could result in a higher serum level. Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Propylthiouracil. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Propylthiouracil. Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Propylthiouracil. Methimazole The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methotrexate. Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Propylthiouracil. Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Propylthiouracil. Methyldopa The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Methyldopa. Methylprednisolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methylprednisolone. Metoclopramide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Metoclopramide. Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Propylthiouracil. Midostaurin The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Midostaurin. Milnacipran The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Milnacipran. Minocycline The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Minocycline. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Propylthiouracil. Mitoxantrone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mitoxantrone. Moderna COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Propylthiouracil. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Propylthiouracil. Mometasone furoate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Monomethyl fumarate. Montelukast The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Propylthiouracil. Mosunetuzumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mosunetuzumab. Mumps virus strain B lev The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Propylthiouracil. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Propylthiouracil. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mycophenolic acid. Nadroparin Propylthiouracil may increase the anticoagulant activities of Nadroparin. Nafarelin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Nafarelin. Naltrexone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Naltrexone. Naphazoline The risk or severity of adverse effects can be increased when Naphazoline is combined with Propylthiouracil. Natalizumab The risk or severity of immunosuppression can be increased when Propylthiouracil is combined with Natalizumab. Nefazodone The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Nelarabine. Neratinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Neratinib. Niacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Niacin. Nilotinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Nilotinib. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Propylthiouracil. Nintedanib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Nintedanib. Nizatidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Nizatidine. Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Propylthiouracil. Norfloxacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Norfloxacin. Nortriptyline The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Nortriptyline. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Propylthiouracil. Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Propylthiouracil. Obinutuzumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Obinutuzumab. Ocrelizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ocrelizumab. Ofatumumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ofatumumab. Ofloxacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ofloxacin. Olaparib The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Olaparib. Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Propylthiouracil. Osimertinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Osimertinib. Ouabain The serum concentration of Ouabain can be increased when it is combined with Propylthiouracil. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Propylthiouracil. Oxtriphylline Propylthiouracil may decrease the excretion rate of Oxtriphylline which could result in a higher serum level. Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Propylthiouracil. Ozanimod The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Paclitaxel. Pacritinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Pacritinib. Palbociclib The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Propylthiouracil. Pamidronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Propylthiouracil. Panobinostat The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Panobinostat. Parnaparin Propylthiouracil may increase the anticoagulant activities of Parnaparin. Paroxetine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Paroxetine. Pazopanib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Propylthiouracil. Pegcetacoplan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pegcetacoplan. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Propylthiouracil. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Propylthiouracil. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pemetrexed. Penicillamine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Penicillamine. Pentosan polysulfate Propylthiouracil may increase the anticoagulant activities of Pentosan polysulfate. Pentostatin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pentostatin. Pentoxifylline Propylthiouracil may decrease the excretion rate of Pentoxifylline which could result in a higher serum level. Perphenazine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Perphenazine. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Propylthiouracil. Pexidartinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Pexidartinib. Phenindione Propylthiouracil may increase the anticoagulant activities of Phenindione. Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Propylthiouracil. Phenprocoumon Propylthiouracil may increase the anticoagulant activities of Phenprocoumon. Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Propylthiouracil. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Propylthiouracil. Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Propylthiouracil. Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Propylthiouracil. Phenytoin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Propylthiouracil. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propylthiouracil. Pirfenidone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pirfenidone. Pirtobrutinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Pirtobrutinib. Pitavastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Pitavastatin. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Propylthiouracil. Pomalidomide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pomalidomide. Ponatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ponesimod. Pralatrexate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pralatrexate. Prasugrel Propylthiouracil may increase the anticoagulant activities of Prasugrel. Pravastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Propylthiouracil. Prednisolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednisone. Procainamide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Procainamide. Procarbazine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Procarbazine. Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Propylthiouracil. Propofol The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Propofol. Protein C Propylthiouracil may increase the anticoagulant activities of Protein C. Protein S human Propylthiouracil may increase the anticoagulant activities of Protein S human. Protriptyline The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Protriptyline. Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Propylthiouracil. Quinupramine The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Quinupramine. Rabies immune gl The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Propylthiouracil. Rabies virus inactivat The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Propylthiouracil. Rabies virus inactivat The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Propylthiouracil. Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Propylthiouracil. Raltegravir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Raltegravir. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Propylthiouracil. Ranitidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ranitidine. Ravulizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ravulizumab. Regorafenib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Regorafenib. Resorcinol The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Resorcinol. Reteplase Propylthiouracil may increase the anticoagulant activities of Reteplase. Reviparin Propylthiouracil may increase the anticoagulant activities of Reviparin. Rilonacept The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Rilonacept. Risankizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Risankizumab. Risedronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Risedronic acid. Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Propylthiouracil. Ritonavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Propylthiouracil. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Propylthiouracil. Rivaroxaban Propylthiouracil may increase the anticoagulant activities of Rivaroxaban. Roflumilast Roflumilast may increase the immunosuppressive activities of Propylthiouracil. Ropeginterferon al The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ropeginterferon alfa-2b. Rosuvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Propylthiouracil. Rozanolixizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Rozanolixizumab. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Propylthiouracil. Ruxolitinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ruxolitinib. Salmeterol The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Salmeterol. Saquinavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Saquinavir. Sarilumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Satralizumab. Secukinumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Secukinumab. Selpercatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Selpercatinib. Selumetinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Selumetinib. Sertraline The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sertraline. Sibutramine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sibutramine. Sildenafil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Propylthiouracil. Siltuximab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Siltuximab. Simvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Simvastatin. Siponimod The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Propylthiouracil. Sirolimus The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sirolimus. Smallpox (Vaccinia) The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Propylthiouracil. Sodium citrate Propylthiouracil may increase the anticoagulant activities of Sodium citrate. Somatotropin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Propylthiouracil. Sorafenib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sorafenib. Spesolimab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Spesolimab. Stavudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Stavudine. Streptokinase Propylthiouracil may increase the anticoagulant activities of Streptokinase. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Propylthiouracil. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Propylthiouracil. Sulfasalazine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sulfasalazine. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Propylthiouracil. Sulodexide Propylthiouracil may increase the anticoagulant activities of Sulodexide. Sunitinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sunitinib. Sutimlimab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sutimlimab. Tacrine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Propylthiouracil. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Propylthiouracil. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Propylthiouracil is combined with Tedizolid phosphate. Temozolomide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Temozolomide. Temsirolimus The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Temsirolimus. Tenecteplase Propylthiouracil may increase the anticoagulant activities of Tenecteplase. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Propylthiouracil. Tepotinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Teprotumumab. Terbinafine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Terbinafine. Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Propylthiouracil. Teriflunomide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Teriflunomide. Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Propylthiouracil. Thalidomide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Thalidomide. Theophylline Propylthiouracil may decrease the excretion rate of Theophylline which could result in a higher serum level. Thiotepa The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Thiotepa. Ticagrelor Propylthiouracil may increase the anticoagulant activities of Ticagrelor. Tick-borne encep The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Propylthiouracil. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Propylthiouracil. Tinzaparin Propylthiouracil may increase the anticoagulant activities of Tinzaparin. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Propylthiouracil. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Propylthiouracil. Tivozanib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tivozanib. Tixocortol The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Tixocortol. Tocilizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Tocilizumab. Tofacitinib Propylthiouracil may increase the immunosuppressive activities of Tofacitinib. Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Propylthiouracil. Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Propylthiouracil. Topotecan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Topotecan. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Propylthiouracil. Trabectedin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trabectedin. Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Propylthiouracil. Trastuzumab emtansine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trastuzumab emtansine. Trazodone The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Trazodone. Triamcinolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Triamcinolone. Triazolam The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Triazolam. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Propylthiouracil. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Propylthiouracil. Triflusal Propylthiouracil may increase the anticoagulant activities of Triflusal. Trilostane The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trilostane. Trimethoprim The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Propylthiouracil. Trimipramine The risk or severity of Cardiac Arrhythmia can be increased when Propylthiouracil is combined with Trimipramine. Tucatinib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tucatinib. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Propylthiouracil. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Propylthiouracil. Typhoid Vi polysacc The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Propylthiouracil. Ubidecarenone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ubidecarenone. Ublituximab The risk or severity of infection can be increased when Ublituximab is combined with Propylthiouracil. Upadacitinib The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Upadacitinib. Urokinase Propylthiouracil may increase the anticoagulant activities of Urokinase. Vandetanib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Vandetanib. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Propylthiouracil. Varicella zoster vaccine The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Propylthiouracil. Vedolizumab The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vedolizumab. Vemurafenib The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Vemurafenib. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Propylthiouracil. Vilanterol The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vilanterol. Vinblastine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vinblastine. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Propylthiouracil. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Propylthiouracil. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Propylthiouracil. Voclosporin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Voclosporin. Vorapaxar Propylthiouracil may increase the anticoagulant activities of Vorapaxar. Vorinostat The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vorinostat. Warfarin Propylthiouracil may increase the anticoagulant activities of Warfarin. Ximelagatran Propylthiouracil may increase the anticoagulant activities of Ximelagatran. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Propylthiouracil. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Propylthiouracil. Zimelidine The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Zimelidine. Pregnancy and Lactation FDA pregnancy category D Pregnant: PTU can cross the placenta and can cause fetal cretinism and goiter. Methimazole causes fetal anatomical abnormalities; hence, if it is necessary to use antithyroid drugs in pregnancy, PTU is preferred in the first trimester with the lowest possible drug dose usage. Due to the increased reported risk of maternal hepatotoxicity from PTU, methimazole is the therapeutic choice in the second and third trimesters.[6][7] Propylthiouracil (PTU) had been considered the antithyroid drug of choice during lactation; however, findings that the rates of liver injury are higher with PTU than with methimazole have altered this judgment. Some experts now recommend that methimazole should be considered the antithyroid drug of choice in nursing mothers. No cases of PTU-induced liver damage have been reported in breastfed infants and it is unknown if the small amounts of the drug in breastmilk can cause liver damage. The drug or breastfeeding should be discontinued if liver toxicity is suspected. Dosages of PTU should be limited to 450 mg daily during breastfeeding. The American Thyroid Association recommends only monitoring infants for appropriate growth and development during routine pediatric health and wellness evaluations and routine assessment of serum thyroid function in the child is not recommended. Rare idiosyncratic reactions (e.g., agranulocytosis) might occur, and the infant should be watched for signs of infection. Monitoring of the infant’s complete blood count and differential is advisable if there is a suspicion of drug-induced blood dyscrasia. Breastfed Infants PTU is excreted in breast milk in small amounts and delivered to infants. There are no clear-cut recommendations for its use in nursing. (AAP suggests it is compatible with nursing while AAFP says it is safe with nursing).[8] A mother was taking oral propylthiouracil 100 mg daily during pregnancy and 125 mg daily after delivery. In her infant, serum thyroxine (T4) concentration dropped slightly below the lower limit of normal on day 4 of life, but both T4 and thyrotropin (TSH) concentrations were normal on day 19 with continued maternal PTU therapy. The drop in T4 was possibly due to propylthiouracil in breastmilk, but more likely from PTU received transplacentally. An infant whose mother was taking propylthiouracil 200 to 300 mg daily was followed for 5 months and found to have normal thyroid function tests. A mother took PTU in a starting dose of 100 mg 3 times daily that was tapered to 50 mg twice daily over a period of 6 months. Her breastfed infant had normal thyroid function tests during this period at the ages of 9 to 13 months of age. Eight mothers taking PTU during pregnancy and doses of 50 to 300 mg daily after delivery exclusively or nearly exclusively breastfed their infants. The infants all had slightly low free T4 levels at birth and TSH levels were above normal in 7 of the 8, indicating that they had been affected by PTU in utero. All of their infants had normal free T4 and TSH levels when measured between 18 days and 8 months of age and none had any adverse effects reported from PTU in milk. The mothers of 11 fully breastfed infants were taking 300 to 750 mg daily of PTU starting at various times between delivery and 11 months postpartum. One infant had a slightly elevated TSH level at 19 weeks of age when his mother was taking PTU 450 mg daily. Two other infants had elevated TSH levels at birth. TSH normalized in both infants with maternal PTU doses of 600 mg daily in one and a dose starting at 300 mg daily at term and increasing to 600 mg daily in the other. Two other infants were reported to be hypothyroid at birth but to have normal thyroid function at 1 month of age despite maternal PTU therapy during breastfeeding. Why is this medication prescribed? Propylthiouracil is used to treat hyperthyroidism (a condition that occurs when the thyroid gland produces too much thyroid hormone, speeding the body’s metabolism, and causing certain symptoms) in adults and children 6 years of age or older. Propylthiouracil is in a class of medications called antithyroid agents. It works by stopping the thyroid gland from making thyroid hormone. How should this medicine be used? Propylthiouracil comes as a tablet to take by mouth. It is usually taken three times a day, once every 8 hours. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take propylthiouracil exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor may decrease your dose of propylthiouracil once your condition is controlled. Continue to take propylthiouracil even if you feel well. Do not stop taking propylthiouracil without talking to your doctor. Other uses for this medicine This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before taking propylthiouracil, tell your doctor and pharmacist if you are allergic to propylthiouracil, any other medications, or any of the ingredients in propylthiouracil tablets. Ask your doctor or pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (‘blood thinners’) such as warfarin (Coumadin), beta blockers such as atenolol (Tenormin), labetalol (Normodyne), metoprolol (Lopressor, Toprol XL), nadolol (Corgard), and propranolol (Inderal); digoxin (Digitek, Lanoxin), and theophylline (Theo-24, Theochron, Theolair). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with propylthiouracil, so be sure to tell your doctor about all the other medications you are taking, even if they do not appear on this list. tell your doctor if you have or have ever had leukopenia (decreased white blood cells) , thrombocytopenia (decreased platelets), or aplastic anemia (condition in which the body does not make enough new blood cells), or other conditions that cause low numbers of red blood cells, white blood cells, or platelets; or liver disease. tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking propylthiouracil, call your doctor.Your doctor may tell you to take propylthiouracil during the first months of your pregnancy only and then may switch you to methimazole for the rest of your pregnancy. Propylthiouracil may cause severe liver problems in pregnant women and may harm the fetus. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking propylthiouracil. What special dietary instructions should I follow? Unless your doctor tells you otherwise, continue your normal diet. What should I do if I forget a dose? Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one. FAQ ◈ What is propylthiouracil? Propylthiouracil (PTU) is an antithyroid medication used to treat hyperthyroidism (too much or overactive thyroid) and Graves’ disease (a common cause of hyperthyroidism). This medication lowers the amount of thyroid hormone that the thyroid gland makes. One brand name for PTU medication is Propycil ®. ◈ I take PTU. Can it make it harder for me to get pregnant? Studies have not been done to see if PTU could make it harder for a woman to get pregnant. Untreated thyroid disorders may make it harder to get pregnant. ◈ I just found out I am pregnant. Should I stop taking PTU? Talk with your healthcare provider(s) before making any changes to this medication. It is important to make sure any medical conditions you have are treated appropriately, especially during pregnancy. Hyperthyroidism can increase the chance of poor outcomes for the pregnancy including miscarriage, preterm delivery, low birth weight, thyroid storm (life-threatening overactive thyroid), and maternal congestive heart failure. ◈ Does taking PTU increase the chance for miscarriage? Miscarriage can occur in any pregnancy. Two studies did not find a higher chance of miscarriage when using PTU during pregnancy. Hyperthyroidism has been associated with an increase in the chance for miscarriage. ◈ Does taking PTU increase the chance of birth defects? In every pregnancy, there is a 3-5% chance of having a baby with a birth defect. This is called the background risk.Studies do not agree if hyperthyroidism itself can increase birth defects. Studies also do not agree if PTU alone can increase birth defects. Some studies suggest there could be a small increase in birth defects of around 2% or less. There has not been a confirmed pattern of birth defects to more strongly suggest cause from PTU exposure alone. Additionally, other studies show no increased chance for birth defects. The FDA and ACOG have noted that PTU may be the preferred treatment for hyperthyroidism during the first trimester of pregnancy.In summary, although studies do not agree, there is not strong evidence to say PTU clearly increases birth defects. You and your healthcare team will decide what is best for your specific situation. ◈ Could taking PTU cause other pregnancy complications? Hyperthyroidism has been found to increase the chance for pregnancy complications like preterm delivery (delivery before week 37) and low birth weight (less than 2lb 3oz). One study did not find a higher chance of preterm delivery when PTU was used during pregnancy. It is not clear if PTU is associated with low birth weight because studies do not agree.Antithyroid medications, like PTU, or having Graves disease, can lead to too low or too high thyroid levels in a baby. If you take PTU, or if you have Grave’s disease, your baby’s thyroid level should be checked after delivery.The FDA has reported that PTU can cause serious liver damage in persons who take PTU including people who are pregnant. You and your healthcare team will decide what is best for your specific situation. ◈ Does taking PTU in pregnancy cause long-term problems in behavior or learning for the baby? Two studies looking at 44 children (from preschool to adult ages) whose parents took PTU during pregnancy found no difference in intelligence scores compared to their unexposed brothers or sisters. Untreated hyperthyroidism in pregnancy can increase the chance of learning problems in children. ◈ Can I breastfeed while taking PTU? PTU gets into breastmilk in small amounts, which means the amounts ingested by the infant are small. The American Thyroid Association has suggested that if PTU is taken while breastfeeding, doses of PTU should be limited to 450 mg per day due to the lack of research on the chance of liver damage in breastfed infants. No adverse effects have been reported in babies whose mothers used PTU while breastfeeding. Studies show that PTU does not significantly affect breastfed infants’ thyroid function. If you are worried about any symptoms that the baby has, contact the child’s healthcare provider.PTU has not been shown to affect milk production. Untreated hyperthyroidism and hypothyroidism may affect milk production. Be sure to talk to your healthcare provider about all of your breastfeeding questions. ◈ I take PTU. Can it make it harder for me to get my partner pregnant or increase the chance of birth defects? Studies have not looked at the chance of fertility effects or birth defects if a father takes PTU. In general, exposures that fathers or sperm donors have are unlikely to increase the risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/006188s021s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/006188s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/006188s021,s022ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006188s025lbl.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Propylthiouracil https://www.mayoclinic.org/drugs-supplements/propylthiouracil-oral-route/side-effects/drg-20072978 https://go.drugbank.com/drugs/DB00550 https://www.ncbi.nlm.nih.gov/books/NBK549828/ https://www.drugs.com/dosage/propylthiouracil.html DrugBank LICENSE Creative Common’s Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) https://www.drugbank.ca/legal/terms_of_use Propylthiouracil https://www.drugbank.ca/drugs/DB00550 Hazardous Substances Data Bank (HSDB) LICENSE https://www.nlm.nih.gov/web_policies.html PROPYL THIOURACIL https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3390 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Propylthiouracil http://www.hmdb.ca/metabolites/HMDB0014690 HMDB0014690_nmr_one_2421 https://hmdb.ca/metabolites/HMDB0014690#spectra CAS Common Chemistry https://creativecommons.org/licenses/by-nc/4.0/ Propylthiouracil https://commonchemistry.cas.org/detail?cas_rn=51-52-5 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Propylthiouracil [USP:INN:BAN:JAN] https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000051525 ChemIDplus Chemical Information Classification https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus DTP/NCI https://www.cancer.gov/policies/copyright-reuse propylthiouracil https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=757302 propylthiouracil https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=70461 propylthiouracil https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=6498 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources 6-Propyl-2-thiouracil https://comptox.epa.gov/dashboard/DTXSID5021209 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Propylthiouracil https://echa.europa.eu/substance-information/-/substanceinfo/100.000.095 Propylthiouracil https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/93880 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking PROPYLTHIOURACIL https://gsrs.ncats.nih.gov/ginas/app/beta/substances/721M9407IY CCSbase https://ccsbase.net/ ChEBI 6-propyl-2-thiouracil http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8502 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes LICENSE https://www.fda.gov/about-fda/about-website/website-policies#linking PROPYLTHIOURACIL https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Propylthiouracil https://www.ncbi.nlm.nih.gov/books/n/livertox/Propylthiouracil/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C781 NCI Thesaurus Tree https://ncit.nci.nih.gov Toxin and Toxin Target Database (T3DB) http://www.t3db.ca/downloads Propylthiouracil http://www.t3db.ca/toxins/T3D4712 ChEMBL (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/). http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1518/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp Propylthiouracil https://ctdbase.org/detail.go?type=chem&acc=D011441 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads PROPYLTHIOURACIL https://www.dgidb.org/drugs/PROPYLTHIOURACIL IUPHAR/BPS Guide to PHARMACOLOGY https://opendatacommons.org/licenses/odbl/. (http://creativecommons.org/licenses/by-sa/4.0/) https://www.guidetopharmacology.org/about.jsp#license propylthiouracil https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6650 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Propylthiouracil https://idrblab.net/ttd/data/drug/details/D00MIN ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ Crystallography Open Database (COD) LICENSE https://creativecommons.org/publicdomain/zero/1.0 DailyMed LICENSE https://www.nlm.nih.gov/copyright.html PROPYLTHIOURACIL https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=PROPYLTHIOURACIL Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking propylthiouracil https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Propylthiouracil https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM230/ Mother To Baby Fact Sheets https://www.ncbi.nlm.nih.gov/books/about/copyright/ propylthiouracil https://www.ncbi.nlm.nih.gov/books/n/mtb/PTU-propylthiouracil-en/ Drugs@FDA https://www.fda.gov/about-fda/about-website/website-policies#linking PROPYLTHIOURACIL https://www.accessdata.fda.gov/scripts/cder/daf/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Medication Guides https://www.fda.gov/about-fda/about-website/website-policies#linking Propylthiouracil https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ https://www.norman-network.com/nds/SLE/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking PROPYLTHIOURACIL https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NMRShiftDB https://pubchem.ncbi.nlm.nih.gov/substance/22389304 SpectraBase 6-propyl-2-thiouracil https://spectrabase.com/spectrum/BeJRY2WFhkA 6-Propyl-2-thiouracil https://spectrabase.com/spectrum/3VV1IvW4fQe 6-PROPYL-2-THIOURACIL https://spectrabase.com/spectrum/7IugXa5gjBR 6-Propyl-2-thiouracil https://spectrabase.com/spectrum/22hijJCDu1M 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo- https://spectrabase.com/spectrum/4nRnUwyLbe4 6-Propyl-2-thiouracil https://spectrabase.com/spectrum/Hw6fnRsLHUi 6-Propyl-2-thiouracil https://spectrabase.com/spectrum/LJbuDuppDdG 6-Propyl-2-thiouracil https://spectrabase.com/spectrum/6dnBVp44cw3 6-propyl-2-thiouracil https://spectrabase.com/spectrum/6988S8wsMew 6-propyl-2-thiouracil https://spectrabase.com/spectrum/2WMzTqSwm4U 6-PROPYL-2-THIOURACIL https://spectrabase.com/spectrum/AHkAxCPFwhi 6-PROPYL-2-THIOURACIL https://spectrabase.com/spectrum/B2W7SrxvHdg URACIL, 6-PROPYL-2-THIO-, https://spectrabase.com/spectrum/KYbyLaKP9TT NIST Mass Spectrometry Data Center LICENSE Data covered by the Standard Reference Data Act of 1968 as amended. https://www.nist.gov/srd/public-law 6-Propyl-2-thiouracil http://www.nist.gov/srd/nist1a.cfm International Agency for Research on Cancer (IARC) https://publications.iarc.fr/Terms-Of-Use Propylthiouracil https://monographs.iarc.who.int/list-of-classifications IARC Classification https://www.iarc.fr/ Japan Chemical Substance Dictionary (Nikkaji) http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J1.363C KEGG https://www.kegg.jp/kegg/legal.html https://www.kegg.jp/entry/C07569 https://www.kegg.jp/entry/D00562 Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drugs listed in the Japanese Pharmacopoeia http://www.genome.jp/kegg-bin/get_htext?br08311.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg MassBank of North America (MoNA) https://mona.fiehnlab.ucdavis.edu/documentation/license 6-Propyl-2-thiouracil https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(compound.metaData.name:%27InChIKey%27%20and%20compound.metaData.value:%27KNAHARQHSZJURB-UHFFFAOYSA-N%27) Metabolomics Workbench Propylthiouracil https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=42886 NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html propylthiouracil https://rxnav.nlm.nih.gov/id/rxnorm/8794 WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ Propylthiouracil https://www.whocc.no/atc_ddd_index/?code=H03BA02 ATC Code https://www.whocc.no/atc_ddd_index/ Pharos https://pharos.nih.gov/about propylthiouracil https://pharos.nih.gov/ligands/TMC3KAZX3T4H Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3CJ PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=11044099-839066573 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=11044071-625616694 The Cambridge Structural Database https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=807160 https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=855965 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=11044099-839066573 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Propylthiouracil https://list.essentialmeds.org/medicines/201 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Propylthiouracil https://www.wikidata.org/wiki/Q377342 Wikipedia Propylthiouracil https://en.wikipedia.org/wiki/Propylthiouracil Wiley https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=9079 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Propylthiouracil https://www.ncbi.nlm.nih.gov/mesh/68011441 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antimetabolites https://www.ncbi.nlm.nih.gov/mesh/68000963 Antithyroid Agents https://www.ncbi.nlm.nih.gov/mesh/68013956 UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html CAMEO Chemicals https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false CAMEO Chemical Reactivity Classification https://cameochemicals.noaa.gov/browse/react EPA Substance Registry Services LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources EPA SRS List Classification https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do PATENTSCOPE (WIPO) SID 403436410 https://pubchem.ncbi.nlm.nih.gov/substance/403436410 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout References